6948-71-6Relevant academic research and scientific papers
NOVEL SYNTHETIC PROCESSES TO 8-CHLORO-3-BENZO[D]AZEPINE VIA FRIEDEL-CRAFTS ALKYLATION OF OLEFIN
-
Page/Page column 37-38, (2014/12/12)
The present invention is directed to a short, facile, effective and industrially applicable process for obtaining 8-chloro-l-methyl-2,3,4,5-tetrahydro-lH- benzo[d]azepine, or its salt, preferably lorcaserin hydrochloride. The present invention is further directed to a simple and effective ring closing methodology for obtaining 8-chloro-l-methyl-2,3,4,5-tetrahydro-lH- benzo[d]azepine, or its salt, preferably lorcaserin hydrochloride. The present invention is also directed to a novel intermediate which can be suitably used in the process for producing 8-chloro-l-methyl-2, 3,4,5- tetrahydro-lH-benzo[d]azepine, or its salt, preferably lorcaserin hydrochloride and to a process for producing the novel intermediate.
Degradation of MAC13243 and studies of the interaction of resulting thiourea compounds with the lipoprotein targeting chaperone LolA
Barker, Courtney A.,Allison, Sarah E.,Zlitni, Soumaya,Nguyen, Nick Duc,Das, Rahul,Melacini, Giuseppe,Capretta, Alfredo A.,Brown, Eric D.
supporting information, p. 2426 - 2431 (2013/05/21)
The discovery of novel small molecules that function as antibacterial agents or cellular probes of biology is hindered by our limited understanding of bacterial physiology and our ability to assign mechanism of action. We previously employed a chemical genomic strategy to identify a novel small molecule, MAC13243, as a likely inhibitor of the bacterial lipoprotein targeting chaperone, LolA. Here, we report on the degradation of MAC13243 into the active species, S-(4-chlorobenzyl)isothiourea. Analogs of this compound (e.g., A22) have previously been characterized as inhibitors of the bacterial actin-like protein, MreB. Herein, we demonstrate that the antibacterial activity of MAC13243 and the thiourea compounds are similar; these activities are suppressed or sensitized in response to increases or decreases of LolA copy number, respectively. We provide STD NMR data which confirms a physical interaction between LolA and the thiourea degradation product of MAC13243, with a K d of ～150 μM. Taken together, we conclude that the thiourea series of compounds share a similar cellular mechanism that includes interaction with LolA in addition to the well-characterized target MreB.
Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a -agonist δ-antagonist and δ-inverse agonists
Cheng, Kejun,Kim, In Jong,Lee, Mei-Jing,Adah, Steven A.,Raymond, Tyler J.,Bilsky, Edward J.,Aceto, Mario D.,May, Everette L.,Harris, Louis S.,Coop, Andrew,Dersch, Christina M.,Rothman, Richard B.,Jacobson, Arthur E.,Rice, Kenner C.
, p. 1177 - 1190 (2008/02/04)
Enantiomeric N-phenethyl-m-hydroxyphenylmorphans with various substituents in the ortho, meta or para positions of the aromatic ring in the phenethylamine side-chain (chloro, hydroxy, methoxy, nitro, methyl), as well as a pyridylethyl and a indolylethyl m
New indole derivatives as factor Xa inhibitors
-
Page/Page column 69, (2008/06/13)
The present invention relates to compounds of formula I, in which R0; R1; R2; R3; R4; R5; R6; R7; Q; V, G and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is indicated. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as pharmaceuticals for treating the foregoing conditions, and pharmaceutical preparations comprising them.
